| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.77▼ | 1.75▲ | 1.74▲ | 1.71▲ | 1.86▼ |
| MA10 | 1.76▲ | 1.73▲ | 1.71▲ | 1.81▼ | 1.94▼ |
| MA20 | 1.75▲ | 1.71▲ | 1.68▲ | 1.92▼ | N/A |
| MA50 | 1.73▲ | 1.68▲ | 1.77▲ | 2.33▼ | N/A |
| MA100 | 1.71▲ | 1.78▼ | 1.90▼ | N/A | N/A |
| MA200 | 1.68▲ | 1.90▼ | 1.93▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.007▲ | 0.019▲ | 0.007▲ | N/A |
| RSI | 61.445▲ | 65.910▲ | 59.793▲ | 38.396▼ | N/A |
| STOCH | 78.889 | 73.830 | 81.567▲ | 16.623▼ | N/A |
| WILL %R | -50.000 | -22.222▲ | -15.000▲ | -71.429 | -92.968▼ |
| CCI | 96.912 | 216.798▲ | 140.552▲ | -72.050 | -69.209 |
|
Wednesday, July 01, 2026 05:00 PM
NervGen Pharma ( (NGEN)) has issued an update. On July 2, 2026, NervGen Pharma filed a Form 6-K with the U.S. Securities and Exchange Commission to report a new sales agreement with Leerink Partners ...
|
|
Tuesday, May 19, 2026 04:20 PM
Detailed price information for Nervgen Pharma Corp (NGEN-Q) from The Globe and Mail including charting and trades.
|
|
Monday, May 18, 2026 04:15 AM
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 20/07/26 | 1.72 | 1.80 | 1.70 | 1.77 | 517,603 |
| 17/07/26 | 1.64 | 1.70 | 1.59 | 1.67 | 857,790 |
| 16/07/26 | 1.69 | 1.73 | 1.61 | 1.67 | 1,471,824 |
| 15/07/26 | 1.76 | 1.79 | 1.68 | 1.69 | 1,315,797 |
| 14/07/26 | 1.995 | 1.995 | 1.73 | 1.74 | 1,305,383 |
| 13/07/26 | 2.03 | 2.06 | 1.90 | 1.93 | 1,128,101 |
| 10/07/26 | 1.93 | 1.94 | 1.80 | 1.88 | 785,473 |
| 09/07/26 | 1.90 | 1.9594 | 1.85 | 1.86 | 778,708 |
| 08/07/26 | 1.98 | 1.99 | 1.84 | 1.85 | 1,465,030 |
| 07/07/26 | 2.10 | 2.10 | 1.99 | 2.01 | 300,117 |
|
|
||||
|
|
||||
|
|